- Home
- DSL vs VRDN Comparison
DSL vs VRDN Comparison
Compare DSL & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSL
- VRDN
- Stock Information
- Founded
- DSL 2013
- VRDN 2006
- Country
- DSL United States
- VRDN United States
- Employees
- DSL N/A
- VRDN N/A
- Industry
- DSL Trusts Except Educational Religious and Charitable
- VRDN Medical Specialities
- Sector
- DSL Finance
- VRDN Health Care
- Exchange
- DSL Nasdaq
- VRDN Nasdaq
- Market Cap
- DSL 1.4B
- VRDN 1.5B
- IPO Year
- DSL N/A
- VRDN N/A
- Fundamental
- Price
- DSL $12.55
- VRDN $18.13
- Analyst Decision
- DSL
- VRDN Buy
- Analyst Count
- DSL 0
- VRDN 12
- Target Price
- DSL N/A
- VRDN $36.44
- AVG Volume (30 Days)
- DSL 412.7K
- VRDN 1.6M
- Earning Date
- DSL 01-01-0001
- VRDN 02-25-2025
- Dividend Yield
- DSL 10.30%
- VRDN N/A
- EPS Growth
- DSL N/A
- VRDN N/A
- EPS
- DSL N/A
- VRDN N/A
- Revenue
- DSL N/A
- VRDN $302,000.00
- Revenue This Year
- DSL N/A
- VRDN $2.55
- Revenue Next Year
- DSL N/A
- VRDN N/A
- P/E Ratio
- DSL N/A
- VRDN N/A
- Revenue Growth
- DSL N/A
- VRDN N/A
- 52 Week Low
- DSL $10.22
- VRDN $11.40
- 52 Week High
- DSL $12.96
- VRDN $27.20
- Technical
- Relative Strength Index (RSI)
- DSL 44.91
- VRDN 44.39
- Support Level
- DSL $12.51
- VRDN $16.60
- Resistance Level
- DSL $12.63
- VRDN $21.58
- Average True Range (ATR)
- DSL 0.11
- VRDN 1.00
- MACD
- DSL 0.00
- VRDN -0.16
- Stochastic Oscillator
- DSL 46.55
- VRDN 30.72
About DSL DoubleLine Income Solutions Fund of Beneficial Interests
DoubleLine Income Solutions Fund is a closed-end management investment company. Its primary investment objective is to seek high income and its secondary objective is to seek capital appreciation. It invests in debt securities and other income-producing investments anywhere in the world, including emerging markets. The company's investment portfolio comprises foreign corporate bonds, U.S. corporate bonds, bank loans, collateralized loan obligations, non-agency commercial mortgage backed obligations, asset-backed obligations, and municipal bonds among others.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. Its product candidate VRDN-001 is an insulin-like growth factor-1 receptor (IGF-1R) monoclonal antibody (mAb) being developed for the potential treatment for patients with thyroid eye disease.